ES2164111T3 - Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares. - Google Patents

Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.

Info

Publication number
ES2164111T3
ES2164111T3 ES95101189T ES95101189T ES2164111T3 ES 2164111 T3 ES2164111 T3 ES 2164111T3 ES 95101189 T ES95101189 T ES 95101189T ES 95101189 T ES95101189 T ES 95101189T ES 2164111 T3 ES2164111 T3 ES 2164111T3
Authority
ES
Spain
Prior art keywords
flupirtine
employment
preparation
active principle
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95101189T
Other languages
English (en)
Spanish (es)
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Jurgen Prof Engel
Peter Dr Emig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva GmbH
Original Assignee
AWD Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AWD Pharma GmbH and Co KG filed Critical AWD Pharma GmbH and Co KG
Application granted granted Critical
Publication of ES2164111T3 publication Critical patent/ES2164111T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
ES95101189T 1990-07-14 1991-07-04 Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares. Expired - Lifetime ES2164111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (enExample) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
ES2164111T3 true ES2164111T3 (es) 2002-02-16

Family

ID=25895002

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95101189T Expired - Lifetime ES2164111T3 (es) 1990-07-14 1991-07-04 Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
ES91111124T Expired - Lifetime ES2082887T3 (es) 1990-07-14 1991-07-04 Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES91111124T Expired - Lifetime ES2082887T3 (es) 1990-07-14 1991-07-04 Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.

Country Status (30)

Country Link
US (2) US5162346A (enExample)
EP (2) EP0467164B1 (enExample)
KR (1) KR0182811B1 (enExample)
CN (1) CN1070700C (enExample)
AT (2) ATE133564T1 (enExample)
AU (1) AU634073B2 (enExample)
CA (1) CA2046943C (enExample)
CZ (1) CZ280879B6 (enExample)
DE (3) DE59109222D1 (enExample)
DK (2) DK0467164T3 (enExample)
EG (1) EG19814A (enExample)
ES (2) ES2164111T3 (enExample)
GR (1) GR3019179T3 (enExample)
HR (1) HRP920667B1 (enExample)
HU (1) HU206973B (enExample)
IE (1) IE74688B1 (enExample)
IL (1) IL98810A (enExample)
IN (1) IN172468B (enExample)
LT (1) LT3593B (enExample)
LV (1) LV10048B (enExample)
MC (1) MC2272A1 (enExample)
MX (1) MX9100160A (enExample)
NO (1) NO912758L (enExample)
NZ (1) NZ238940A (enExample)
PT (1) PT98291B (enExample)
RO (1) RO108220B1 (enExample)
RU (1) RU2070408C1 (enExample)
SI (1) SI9111227B (enExample)
SK (1) SK279567B6 (enExample)
ZA (1) ZA915466B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CN1399550A (zh) * 1999-08-03 2003-02-26 Awd药品股份有限两合公司 氟吡氨酯在减轻猫或犬退行性关节病相关性疼痛中的应用
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
CN101247795B (zh) * 2005-04-06 2012-02-01 埃德莫斯药品有限公司 用于治疗与中枢神经系统（cns）相关疾病的方法和组合物
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
CN101563085A (zh) * 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
NZ577740A (en) * 2006-11-28 2012-06-29 Valeant Pharmaceuticals Int 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
AR070513A1 (es) * 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
EP4054580A1 (en) 2019-11-08 2022-09-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
PE20231815A1 (es) 2021-02-09 2023-11-16 Xenon Pharmaceuticals Inc Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
DE59107331D1 (de) 1996-03-14
GR3019179T3 (en) 1996-06-30
NO912758D0 (no) 1991-07-12
IL98810A0 (en) 1992-07-15
DK0467164T3 (da) 1996-03-04
CZ280879B6 (cs) 1996-04-17
LV10048B (en) 1995-06-20
ATE133564T1 (de) 1996-02-15
SI9111227A (en) 1995-06-30
CN1070700C (zh) 2001-09-12
CN1058716A (zh) 1992-02-19
HRP920667A2 (en) 1996-10-31
LTIP919A (en) 1995-03-27
DK0659410T3 (da) 2001-12-27
KR920002147A (ko) 1992-02-28
KR0182811B1 (ko) 1999-05-01
DE59109222D1 (de) 2001-11-22
HU912359D0 (en) 1991-12-30
HRP920667B1 (en) 1998-06-30
EP0659410B1 (de) 2001-10-17
EP0659410A3 (de) 1995-10-25
EG19814A (en) 1996-02-29
ES2082887T3 (es) 1996-04-01
US5284861A (en) 1994-02-08
NZ238940A (en) 1997-05-26
IL98810A (en) 1996-01-19
IE912451A1 (en) 1992-01-15
ZA915466B (en) 1992-04-29
CS210191A3 (en) 1992-02-19
RU2070408C1 (ru) 1996-12-20
HU206973B (en) 1993-03-01
IN172468B (enExample) 1993-08-14
IE74688B1 (en) 1997-07-30
ATE206919T1 (de) 2001-11-15
RO108220B1 (ro) 1994-03-31
PT98291B (pt) 1999-01-29
NO912758L (no) 1992-01-15
SK279567B6 (sk) 1999-01-11
CA2046943A1 (en) 1992-01-15
LV10048A (lv) 1994-05-10
US5162346A (en) 1992-11-10
AU8040391A (en) 1992-01-16
LT3593B (en) 1995-12-27
EP0467164A3 (en) 1992-04-15
EP0467164A2 (de) 1992-01-22
SI9111227B (sl) 2000-12-31
MX9100160A (es) 1992-02-28
MC2272A1 (fr) 1993-06-23
CA2046943C (en) 1996-03-12
EP0659410A2 (de) 1995-06-28
HUT59313A (en) 1992-05-28
PT98291A (pt) 1992-05-29
AU634073B2 (en) 1993-02-11
DE4122166A1 (de) 1992-01-16
EP0467164B1 (de) 1996-01-31

Similar Documents

Publication Publication Date Title
ES2164111T3 (es) Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
ATE69376T1 (de) Haarwuchsmittel.
BR9708815A (pt) Composições farmacêuticas para prevenção e tratamento de desordens do sistema nervoso central.
BR1100384A (pt) Composto e formulação farmacêutica
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
ES537300A0 (es) Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
ES2128043T3 (es) Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral.
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
DK671087A (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
SE8301038D0 (sv) Tiopyranopyrimidinforeningar och syraadditionssalter derav
ES2161745T3 (es) Utilizacion de la trimetazidina para la obtencion de medicamentos destinados para el tratamiento de los trastornos relacionados con la nefrotoxicidad de la ciclosporina a.
DE69833317D1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659410

Country of ref document: ES